Eishi Baba

Eishi Baba

Auto-generated profile, based on publicly available information

Eishi Baba

Department of Comprehensive Oncology, Graduate School of Medical Sciences, Kyushu University, Japan

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2024 in ESMO Open
Verified
Journal Article
Open access
KSKohei Shitara
Kohei Shitara
TFTania Fleitas
Tania Fleitas
HKH. Kawakami
H. Kawakami
GCGiuseppe Curigliano
Giuseppe Curigliano
YNYukiya Narita
Yukiya Narita
ESE. Smyth
E. Smyth
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer (GC), published in late 2022 and the updated ESMO Gastric Cancer Living Guideline published in July 2023, were adapted in August 2023, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with GC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with GC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), coordinated by ESMO and the Japanese Society of Medical Oncology (JSMO). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different Asian regions represented by the 10 oncological societies. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with GC across the different regions of Asia, drawing on the evidence provided by both Western and Asian trials, whilst respecting the differences in screening practices, molecular profiling and age and stage at presentation. Attention is drawn to the disparity in the drug approvals and reimbursement strategies, between the different regions of Asia.

4 September 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
MNMichitaka Nakano
Michitaka Nakano
YKYoshikane Kikushige
Yoshikane Kikushige
KMKohta Miyawaki
Kohta Miyawaki
YKYuya Kunisaki
Yuya Kunisaki
SMShinichi Mizuno
Shinichi Mizuno
KAKoichi Akashi
Koichi Akashi

1 September 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
NTNobuhiro Tsuruta
Nobuhiro Tsuruta
KTKenji Tsuchihashi
Kenji Tsuchihashi
HOHirofumi Ohmura
Hirofumi Ohmura
KYKyoko Yamaguchi
Kyoko Yamaguchi
MIMamoru Ito
Mamoru Ito
EBEishi Baba
Eishi Baba

1 January 2020 in OncoImmunology
Verified
Journal Article
Open access
KYKyoko Yamaguchi
Kyoko Yamaguchi
MIMamoru Ito
Mamoru Ito
HOHirofumi Ohmura
Hirofumi Ohmura
FHFumiyasu Hanamura
Fumiyasu Hanamura
MNMichitaka Nakano
Michitaka Nakano
EBEishi Baba
Eishi Baba
Tertiary lymphoid structures (TLSs), clusters of immune cells found around tumor tissue, have been shown to be associated with anti-tumor immunity, but the cellular composition within each TLS and whether the cellular composition of a TLS affects a patient’s prognosis are poorly understood. In the present study, each TLS was categorized according to its cellular composition determined by a system of multiplex immunohistochemical staining and quantitative analysis, and the correlation between the category and prognosis was examined. Sixty-seven patients with curatively resected stage II/III colorectal cancer (CRC) were enrolled. A TLS, consisting of germinal center B cells, follicular dendritic cells, T helper (Th) cells, B cells, cytotoxic T cells, and macrophages, was confirmed in the tumor tissue of 58 patients (87%). The densities of Th cells and macrophages were significantly higher in relapsed patients than in not-relapsed patients (p = .043 and p = .0076). A higher ratio of Th cells was the most significant independent risk factor for disease relapse on multivariate analysis. The subset increasing in Th cells was GATA3+ Th2. A total of 353 TLSs was divided into five clusters according to immune cell composition. Among them, the Th-rich type TLS was significantly increased (p = .0009) in relapsed patients. These data suggest the possibility that Th cell-dominant composition might disturb the anti-tumor immune response, and the function of each TLS might differ depending on its composition.

1 August 2018 in Cancer Science
Verified
Journal Article
Open access
PDF file
KYKyoko Yamaguchi
Kyoko Yamaguchi
KMKoji Mishima
Koji Mishima
HOHirofumi Ohmura
Hirofumi Ohmura
FHFumiyasu Hanamura
Fumiyasu Hanamura
MIMamoru Ito
Mamoru Ito
EBEishi Baba
Eishi Baba
Human anti‐programmed death‐1 (PD‐1) antibody possesses the capability to revitalize host T cells and has been an effective therapy for metastatic malignant melanoma (MM). The precise subsets of T cells predominantly activated by anti‐PD‐1, however, have not yet been clarified. In this study, peripheral blood mononuclear cells obtained from MM patients scheduled to receive anti‐PD‐1 (nivolumab) therapy, and healthy subjects (HS), were systematically examined on flow cytometry to identify changes in the proportion of immune cell subsets. Compared with HS, MM patients prior to therapy had an increased proportion of activated CD8+ T cells with effector memory phenotypes (Tem), and PD‐1 positive subsets of CD4+ central memory T cells (Tcm) and T‐helper (Th)17 cells. After a single course of anti‐PD‐1 therapy, MM patients had an increase in activated Tem and Tcm subsets of CD4+ and CD8+ T cells, and activated Th1 plus T‐helper follicular 1 cells. There was no consistent change in the proportion of Tfh cells, B cells, natural killer cells, or dendritic cells. The observed activated phenotypes were attenuated during the course of therapy, but regulatory T cells belonging to the CD3+CD4+CD45RO+CD25high fraction increased at disease progression. Taken together, anti‐PD‐1 therapy modulates systemic immune reactions and exerts anti‐tumor effects, not only by revitalizing Tem and Tcm of CD4+ and CD8+ T cells, but also via a shift to a Th1 phenotype.

23 March 2020 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
HOHirofumi Ohmura
Hirofumi Ohmura
KYKyoko Yamaguchi
Kyoko Yamaguchi
FHFumiyasu Hanamura
Fumiyasu Hanamura
MIMamoru Ito
Mamoru Ito
AMAkitaka Makiyama
Akitaka Makiyama
EBEishi Baba
Eishi Baba
Background: Anti-PD-1 monoclonal antibody, nivolumab, has shown efficacy for advanced gastric cancer (AGC). However, the specific immune cell subsets predominantly activated during the period of anti-PD-1 therapy for AGC have not been clarified. Methods: Peripheral blood of 30 AGC patients treated with nivolumab was prospectively obtained before the initial and second administrations and at the time of progressive disease (PD). The proportions of immune cell subsets and the serum concentrations of cytokines were systematically analysed by flow cytometry. Associations of subsets and serum cytokines with therapeutic effects were evaluated. Results: After the initial administration, significant increases in activated central/effector memory, activated effector T cells, and activated T-helper 1 subsets were observed. At the time of PD, activated regulatory T cells, LAG3-positive CD4+/CD8+ T cells, and TIM3-positive CD4+/CD8+ T cells increased significantly. Significant positive correlations were shown between progression-free survival and proportions of LAG3-positive CD4+/CD8+ T cells and of OX40-positive CD4+/CD8+ T cells (log-rank p = 0.0008, 0.0003, 0.0035 and 0.0040). Conclusions: Nivolumab therapy enhances activation of central/effector memory and effector subsets of CD4+/CD8+ T cells. The expression levels of LAG-3 and OX40 on T cells correlated with the efficacy of nivolumab therapy and could be reasonable biomarkers for anti-PD-1 therapy.